2.88

0.35% -0.01

After Hours: 2.94 0.06 +2.08%

Aadi Bioscience Inc (AADI)

Overview News Price History Option Chain Financials Why AADI Down? Discussions Forecast Stock Split

Aadi Bioscience Inc stock is traded at $2.88, with a volume of 175.25K. It is down -0.35% in the last 24 hours and down -2.70% over the past month. Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Previous Close:

$2.89

Open:

$2.89

24h Volume:

175.25K

Relative Volume:

0.54

Market Cap:

$71.08M

Revenue:

$23.26M

Net Income/Loss:

$-63.41M

P/E Ratio:

-1.2203

EPS:

-2.36

Net Cash Flow:

$-64.56M

1W Performance:

-4.95%

1M Performance:

-2.70%

6M Performance:

+84.62%

1Y Performance:

+61.80%

1-Day Range:

$2.80

$2.97

1-Week Range:

$2.80

$3.141

52-Week Range:

$1.21

$3.812

Aadi Bioscience Inc Stock (AADI) Company Profile

Name

Aadi Bioscience Inc

Sector

Healthcare (1174)

Industry

Biotechnology (678)

Phone

424-473-8055

Address

17383 SUNSET AVENUE, PACIFIC PALISADES

Employee

Twitter

Next Earnings Date

2024-12-06

Latest SEC Filings

AADI's Discussions on Twitter

Compare AADI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AADI Aadi Bioscience Inc	2.88	71.08M	23.26M	-63.41M	-64.56M	-2.36
VRTX Vertex Pharmaceuticals Inc	438.40	112.90B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	683.08	75.06B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	665.68	40.45B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	277.16	35.75B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	120.88	28.98B	3.30B	-501.07M	1.03B	-2.1146

Aadi Bioscience Inc Stock (AADI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-27-24	Downgrade	Piper Sandler	Overweight → Neutral
Aug-21-24	Downgrade	Jefferies	Buy → Hold
Aug-21-24	Downgrade	TD Cowen	Buy → Hold
Dec-15-23	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-11-22	Initiated	Jefferies	Buy
Oct-01-21	Initiated	Cowen	Outperform
Sep-14-21	Initiated	Ladenburg Thalmann	Buy
Sep-08-21	Initiated	Piper Sandler	Overweight

View All

Aadi Bioscience Inc Stock (AADI) Latest News

Jan 29, 2025

Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Large Increase in Short Interest - Defense World

Jan 29, 2025

Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Significant Growth in Short Interest - MarketBeat

Jan 29, 2025

Jan 24, 2025

ACUTA CAPITAL PARTNERS, LLC Expands Stake in Aadi Bioscience Inc - GuruFocus.com

Jan 24, 2025

Jan 16, 2025

Aadi Bioscience, Inc. (NASDAQ:AADI) Position Lowered by Jane Street Group LLC - Defense World

Jan 16, 2025

Aadi Bioscience, Inc. (NASDAQ:AADI) Shares Sold by Jane Street Group LLC - MarketBeat

Jan 16, 2025

Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Rises By 136.0% - Defense World

Jan 16, 2025

Jan 14, 2025

Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Grows By 136.0% - MarketBeat

Jan 14, 2025

Aadi Bioscience (NASDAQ:AADI) Shares Down 16.1% – What’s Next? - Defense World

Jan 14, 2025

Aadi Bioscience (NASDAQ:AADI) Trading Down 16.1%What's Next? - MarketBeat

Jan 14, 2025

Dec 23, 2024

Aadi Bioscience Enters Into Multiple Strategic Agreements, Including $100M Stock Purchase and License Agreement - Defense World

Dec 23, 2024

Aadi Bioscience, Inc. announced that it expects to receive $100.002392 million in funding from a group of investors - Marketscreener.com

Dec 23, 2024

Aadi Bioscience Sale of FYARRO® to Kaken Pharmaceutical and In-Licensing of Novel ADC Portfolio from WuXi Biologics - Leerink Partners

Dec 23, 2024

Dec 22, 2024

Wilson Sonsini Advises Aadi Bioscience on $100 Million Sale of FYARRO®, $100 Million PIPE Financing and License Agreement for ADC Portfolio - Wilson Sonsini

Dec 20, 2024

Asia Deal Watch: Kaken Obtains Aadi Subsidiary And Cancer Drug Fyarro - Citeline

Dec 20, 2024

Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday? - Benzinga

Dec 20, 2024

Aadi Bioscience stock soars on licensing and sale deals - Investing.com India

Dec 20, 2024

Aadi Bioscience stock soars on licensing and sale deals By Investing.com - Investing.com UK

Dec 20, 2024

Dec 19, 2024

Aadi Bioscience, Inc. Appoints Baiteng Zhao to its Board of Directors - Marketscreener.com

Dec 19, 2024

Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing - Yahoo Finance

Dec 19, 2024

Kaken Pharmaceutical Co., Ltd. agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. for $100 million. - Marketscreener.com

Dec 19, 2024

Clinical Trials News Live Feed - StockTitan

Dec 19, 2024

Dec 15, 2024

Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Update - MarketBeat

Dec 15, 2024

Dec 11, 2024

AADI Enlists NY Court To Enforce Cancer Drug Award - Law360

Dec 11, 2024

Dec 03, 2024

Aadi Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Dec 03, 2024

Dec 02, 2024

Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Decreases By 8.8% - MarketBeat

Dec 02, 2024

Nov 26, 2024

GSA Capital Partners LLP Cuts Stake in Aadi Bioscience, Inc. (NASDAQ:AADI) - Defense World

Nov 26, 2024

Nov 19, 2024